Ionis Pharmaceuticals IONS Upfront Royalty Payment Received
Upfront Royalty Payment Received at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept ions:UpfrontRoyaltyPaymentReceived.
The official record: Ionis Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's upfront royalty payment received.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's upfront royalty payment received?
- Ionis Pharmaceuticals (IONS) reported upfront royalty payment received of $500M in Q1 2023.
- What does upfront royalty payment received mean?
- One-time cash payments received from partners for licensing the company's technology.
- How do you interpret upfront royalty payment received?
- An increase signals strong market demand for the company's R&D pipeline and successful business development efforts.
- How does upfront royalty payment received compare across companies?
- Common in biotech and pharma; peers often report these as 'Collaboration Revenue' or 'Upfront Licensing Fees'.